Drug discount agreements pursuant to § 130a para. 8 SGB V within the framework of open house procedures
Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren — original title
DEGermany · Dresden
Open-house procedure. Any company meeting the conditions can join the contract — there is no competition for an award. The date shown is the end of the joining phase or of the contract term.
Your path to submission
Deadline: 5 July 2028 at 23:59 — 613 days left.
You submit on Vergabemarktplatz (cosinex) — not here and not by e-mail. ↗ Free bidder account on the cosinex platform required (created instantly); offers go through the bidding tool, usually plain text form suffices — no qualified signature. Sort out account and signature first — not on submission day.
Offer and evidence in: German.
Collect your evidence — use the eligibility analysis on this page: it lists the requirements and, for known certificates, how to get them.
Compiled automatically from notice and documents — no guarantee; the procedure's wording is binding.
What the buyer is looking for
IKK classic hereby announces that it will conclude non-exclusive discount agreements with all interested and suitable pharmaceutical companies in the period from 01.09.2026 to 31.08.2028 on various active substances and combinations of active substances in accordance with Section 130a(8) SGB V on equal, non-negotiable terms. The earliest contract start date is 01.09.2026, provided that the signed contract and all necessary proofs, self-declarations and documents are received by the IKK classic by 07.08.2026. Thereafter: Upon receipt of the documents by the 5th of each month in the possible accession period, the 1st of the following month will be the beginning of the contract. Upon receipt of the documents after the 5th of each month in the possible accession period, the 1st of the following month will be the beginning of the contract. Accession to the agreement is possible at any time during the specified period, but at the latest by 05.07.2028. For further information, see point VI.3).
Machine translation (EU eTranslation) — official wording via the PDF link.
In this sector the buyer awards roughly every 2 months (1000 awards, most recently September 2026) — the next award is due around November 2026 by that rhythm. The last award went to G.L. Pharma Deutschland GmbH.n = 1,000
66% of this buyer's awards went to companies that had already won here before (1,780 awards since 2018, spread over 608 companies). 34% went to new names.n = 1,780 awards since 2018
The award came in at a median 70% of the estimated value (7 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 7
The median procedure drew 2 bids (1,753 procedures with a bid count); 43% ended with a single bidder. Sector: median 2 bids.n = 1,753
< 1% of the bids received came from other countries (144 procedures with a bid mix) — all bidders, not just the winners. Sector: 5%.n = 144
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 25/10/2026.
Clement
References and certificates from your home country count fully across the EU — that is what European procurement law is for.
What you must prove — eligibility criteria
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
›
Quality control by institutes
Gemäß § 130a Abs.8 Satz 1 SGB V ist das Verfahren nur an pharmazeutische Unternehmer (oder Bietergemeinschaften pharmazeutischer Unternehmer) im Sinne des § 4 Abs. 18 AMG gerichtet.
Requirement texts are quoted in the notice's original language — only the official wording is binding.
When this buyer has awarded in this sector, usually 17 or more bids came in. Many compete here — price and references decide. (Based on 1,477 completed awards — not a statement about this procedure.)
This procedure allows 675 days between publication and deadline — typical in this country is 32 (median of 20,071 procedures). Much more generous than usual — time for a thorough bid rather than a quick one.
In Germany · Medical equipment & pharma, 270 contracts went to foreign companies over the last 3 years (of 22,355 recorded awards) — mostly from Austria, Netherlands, France.
Submission language: German.
Measured from linked award data; foreign winners bidding through a local subsidiary count as domestic — the true share is higher.
We pull data from millions of notices. If the link here does not work, report it — we will find the right one.
Don't miss the next one
Friedrich finds tenders like this for you — every morning at 7:30, each one checked by Claude (Anthropic) for fit, and he learns from your feedback what your company really does.